• Suspected cognitive impairment/dementia

• Early Alzheimer's patients

• Parkinson's & movement disorders

• Lewy body & vascular dementia

• Hydrocephalus & degenerative diseases

• Caregivers and families

Show Chwan Memorial Hospital's International Dementia and Movement Disorders Center, led by Director Pai-Yi Chiu, has developed HAICDDS (History-based Artificial Intelligent Clinical Dementia Diagnostic System) — a structured 105-question clinical history tool designed per international diagnostic criteria. The AI system completes assessment in 15-25 minutes, automatically classifying cognitive decline severity and type, covering ~90% of dementia types including Alzheimer's, vascular, Lewy body, Parkinson's disease dementia, and hydrocephalus. The platform integrates with Show Chwan's Brain Disease Expert System, linking cognitive, imaging, biomarker, neuropsychiatric symptom, motor, sleep, and quality of life databases — accumulating 30,000+ clinical entries. Services include dementia clinics, education, family fellowships, academic lectures, and long-term follow-up. International collaborations with Prof. Hiroshi Matsuda (Japan National Center of Neurology), Prof. Sheng-Ping Mok (University of Macau), Prof. Chuan-Tao Zuo (Fudan Huashan Shanghai). Published 29+ SCI papers. System-physician diagnostic concordance: ~80%.

• AI dementia diagnosis with simultaneous classification and grading

• Covers ~90% of dementia types

• Integrated psychological, imaging, biomarker DB

• Dual integration with expert system

• Cross-national neuroimaging research team

• ExAblate Neuro focused ultrasound therapy

• Clinical database: 30,000+ entries

• 105 structured history questions

• Assessment time: 15-25 minutes

• 30+ professionals collecting data

• 2022: 3 integrated projects, 2024: 4

• Monthly revenue increase: NT$180-200k

• System-physician concordance: ~80%

• Dementia type recognition improved 70%

• 6-year treatment CASI decline only 3.83%

• MMSE increased 2.83% over 6 years

• HAIADL daily function increased 3.45%

• Monthly dementia drug revenue +NT$100k

• Patient safety SOP established

• Compliance with patient safety regulations

• De-identified imaging protects privacy

• 6-year long-term stable follow-up

• No significant cognitive deterioration

• Structured database reduces human error

• 38 patient/family satisfaction surveys

• High affirmation of physician expertise

• Positive feedback on diagnosis and education

• Continuous family fellowship participation

• Online program interview: 44,000 views

• Show-Wisdom Senior Salon dementia art exhibit

• Collaboration with Prof. Hiroshi Matsuda (Japan NCNP)

• Deep learning collaboration with Prof. SP Mok (UM)

• Exchange with Prof. CT Zuo (Fudan Huashan)

• Cross-national neuroimaging team (CN-JP-TW)

• Hosted Asian Nuclear Medicine Annual Meeting

• 29+ SCI papers, many with 50+ citations

• Resolves time-consuming, expensive traditional diagnosis

• Improves early recognition accuracy

• Drives dementia drug program growth

• Trains cross-national research and clinical talent

• Patent application: "Facial image neurodegenerative risk assessment" (113130527)